Polyclone Bio Services Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.92 M
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 2.50 M
About Polyclone Bio Services
Polyclone Bio Services Private Limited (PBSPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 December 2003 and has a history of 21 years and one month. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.92 M.
The company currently has active open charges totaling ₹2.50 M.
Naveen Kulkarni, Rajendra Praveen, and Sanjay Shripathy serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100KA2003PTC033096
-
Company No.
033096
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Dec 2003
-
Date of AGM
30 Sep 2017
-
Date of Balance Sheet
31 Mar 2017
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Polyclone Bio Services?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveen Kulkarni
|
Managing Director | 26-Dec-2003 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Rajendra Praveen
|
Director | 08-Apr-2005 | Current |
|
Sanjay Shripathy
|
Director | 26-Dec-2003 | Current |
Financial Performance of Polyclone Bio Services.
Polyclone Bio Services Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Polyclone Bio Services?
In 2017, Polyclone Bio Services had a promoter holding of 43.68% and a public holding of 56.32%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Quantumzyme LlpNaveen Kulkarni is a mutual person
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2006 | State Bank Of India | ₹2.50 M | Open |
How Many Employees Work at Polyclone Bio Services?
Unlock and access historical data on people associated with Polyclone Bio Services, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Polyclone Bio Services, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Polyclone Bio Services's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.